Preparation of monoclonal antibodies against Epstein-Barr virus glycoprotein 350.

IF 1.9 4区医学 Q3 GENETICS & HEREDITY

Virus Genes Pub Date : 2023-10-01 Epub Date: 2023-06-16 DOI:10.1007/s11262-023-02013-y

Jiao Zheng, Xuan Zeng, Linxiu Zeng, Ye Xu, Zhihong Zhong, Yi Wu, Yilan Qiu, Rushi Liu

{"title":"Preparation of monoclonal antibodies against Epstein-Barr virus glycoprotein 350.","authors":"Jiao Zheng, Xuan Zeng, Linxiu Zeng, Ye Xu, Zhihong Zhong, Yi Wu, Yilan Qiu, Rushi Liu","doi":"10.1007/s11262-023-02013-y","DOIUrl":null,"url":null,"abstract":"Epstein-Barr virus (EBV) is the first identified human oncogenic herpesvirus infecting over 90% of the adults worldwide. However, the safe and effective prophylactic vaccine has not been licensed. The major glycoprotein 350 (gp350) on the EBV envelope is the main target for neutralizing antibodies, and gp350 (aa15-320) was used for the development of monoclonal antibodies in present study. The purified recombinant gp35015-320aa with an estimated molecular weight of 50 kDa was used to immunize six-week-old BALB/c mice, and the hybridoma cell lines that stably secreted monoclonal antibodies (mAbs) were obtained. The ability of developed mAbs for capturing and neutralizing EBV was evaluated, and mAb 4E1 presented better performance to block the infection of EBV in cell line Hone-1. The mAb 4E1 recognized the epitope. Its sequence of variable region genes (VH and VL) presented a unique identity which hadn't been reported. The developed mAbs might benefit the antiviral therapy and immunologic diagnosis for EBV infection.","PeriodicalId":51212,"journal":{"name":"Virus Genes","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virus Genes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11262-023-02013-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Epstein-Barr virus (EBV) is the first identified human oncogenic herpesvirus infecting over 90% of the adults worldwide. However, the safe and effective prophylactic vaccine has not been licensed. The major glycoprotein 350 (gp350) on the EBV envelope is the main target for neutralizing antibodies, and gp350 (aa15-320) was used for the development of monoclonal antibodies in present study. The purified recombinant gp350^15-320aa with an estimated molecular weight of 50 kDa was used to immunize six-week-old BALB/c mice, and the hybridoma cell lines that stably secreted monoclonal antibodies (mAbs) were obtained. The ability of developed mAbs for capturing and neutralizing EBV was evaluated, and mAb 4E1 presented better performance to block the infection of EBV in cell line Hone-1. The mAb 4E1 recognized the epitope. Its sequence of variable region genes (V_H and V_L) presented a unique identity which hadn't been reported. The developed mAbs might benefit the antiviral therapy and immunologic diagnosis for EBV infection.

Abstract Image

查看原文本刊更多论文

抗Epstein-Barr病毒糖蛋白350单克隆抗体的制备。

EB病毒是第一种被发现的人类致癌疱疹病毒，感染了全球90%以上的成年人。然而，这种安全有效的预防性疫苗尚未获得许可。EBV包膜上的主要糖蛋白350（gp350）是中和抗体的主要靶点，gp350（aa15-320）用于开发单克隆抗体。将纯化的重组gp35015-320aa（估计分子量为50kDa）用于免疫6周龄的BALB/c小鼠，获得了稳定分泌单克隆抗体（mAb）的杂交瘤细胞系。评估了所开发的mAb捕获和中和EBV的能力，并且mAb 4E1在细胞系Hone-1中表现出更好的阻断EBV感染的性能。mAb 4E1识别该表位。它的可变区基因序列（VH和VL）呈现出一种尚未报道的独特身份。所开发的单克隆抗体可能有利于EBV感染的抗病毒治疗和免疫诊断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Virus Genes 医学-病毒学

CiteScore

3.30

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： Viruses are convenient models for the elucidation of life processes. The study of viruses is again on the cutting edge of biological sciences: systems biology, genomics, proteomics, metagenomics, using the newest most powerful tools. Huge amounts of new details on virus interactions with the cell, other pathogens and the hosts – animal (including human), insect, fungal, plant, bacterial, and archaeal - and their role in infection and disease are forthcoming in perplexing details requiring analysis and comments. Virus Genes is dedicated to the publication of studies on the structure and function of viruses and their genes, the molecular and systems interactions with the host and all applications derived thereof, providing a forum for the analysis of data and discussion of its implications, and the development of new hypotheses.